title: [The therapeutic effects of FLAG regime for refractory and relapsing acute leukemia].
abstract: OBJECTIVE
  To investigate the therapeutic effects of FLAG regimen for refractory and relapsing acute leukemia.
  
  
  METHODS
  Fludarabine 30 mg.m(-2).d(-1), 3 - 5 days, Ara-C 1.5 g.m(-2).d(-1), 5 d and, G-CSF 5 microg.kg(-1).d(-1) were used to treat 7 cases (10 times) of refractory and relapsed leukemia.
  
  
  RESULTS
  Of the 10 times, nine showed response to therapy; one case died of complication. Neutropenia begin at the time of 5 - 12 days after the regimen initiating and last 5 - 34 days, thrombocytopenia begin at 5 - 18 days and last 5 - 36 days. The adverse reaction includes hyperamino transferase, pyrexia and diarrhea.
  
  
  CONCLUSIONS
  FLAG shows obvious effects for refractory and relapsing acute leukemia and gains time for hematopoietic stem cell transplantation.
authors.affiliation: Institute of Hematology and People' Hospital, Peking University, Beijing 100044, China. xjhrm@medmail.com.cn
authors.forename: Xiao-jun
authors.initials: XJ
authors.lastname: Huang
authors.forename: Jin
authors.initials: J
authors.lastname: Lu
authors.forename: Dao-pei
authors.initials: DP
authors.lastname: Lu
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D014740:Vidarabine